Evidence map›Paper›PMID 37953291›Full record

ArticleBMC medicine2023

A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran.

Mahan Ghafari, Sepanta Hosseinpour, Mohammad Saeid Rezaee-Zavareh, Stefan Dascalu, Somayeh Rostamian, Kiarash Aramesh, Kaveh Madani, Shahram Kordasti

Abstract read
In one paragraph

Article in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mahan GhafariBig Data Institute and Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. mahan.ghafari@ndm.ox.ac.uk.ORCID 0000-0002-4123-3287
Sepanta HosseinpourSchool of Dentistry, The University of Queensland, Herston, QLD 4006, Australia.
Mohammad Saeid Rezaee-ZavarehMiddle East Liver Diseases (MELD) Center, Tehran, Iran.
Stefan DascaluDepartment of Biology, University of Oxford, Oxford, UK.
Somayeh RostamianDepartment of Medicine, National Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-7584-9493
Kiarash ArameshThe James F. Drane Bioethics Institute, PennWest University, Edinboro, PA, USA.
Kaveh MadaniUnited Nations University Institute for Water, Environment and Health (UNU-INWEH), Hamilton, ON, Canada.
Shahram KordastiComprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK. shahram.kordasti@kcl.ac.uk.ORCID 0000-0002-0347-4207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccination has played a pivotal role in reducing the burden of COVID-19. Despite numerous studies highlighting its benefits in reducing the risk of severe disease and death, we still lack a quantitative understanding of how varying vaccination roll-out rates influence COVID-19 mortality.

methodsWe developed a framework for estimating the number of avertable COVID-19 deaths (ACDs) by vaccination in Iran. To achieve this, we compared Iran's vaccination roll-out rates with those of eight model countries that predominantly used inactivated virus vaccines. We calculated net differences in the number of fully vaccinated individuals under counterfactual scenarios where Iran's per-capita roll-out rate was replaced with that of the model countries. This, in turn, enabled us to determine age specific ACDs for the Iranian population under counterfactual scenarios where number of COVID-19 deaths are estimated using all-cause mortality data. These estimates covered the period from the start of 2020 to 20 April 2022.

resultsWe found that while Iran would have had an approximately similar number of fully vaccinated individuals under counterfactual roll-out rates based on Bangladesh, Nepal, Sri Lanka, and Turkey (~ 65-70%), adopting Turkey's roll-out rates could have averted 50,000 (95% confidence interval: 38,100-53,500) additional deaths, while following Bangladesh's rates may have resulted in 52,800 (17,400-189,500) more fatalities in Iran. Surprisingly, mimicking Argentina's slower roll-out led to only 12,600 (10,400-13,300) fewer deaths, despite a higher counterfactual percentage of fully vaccinated individuals (~ 79%). Emulating Montenegro or Bolivia, with faster per capita roll-out rates and approximately 50% counterfactual full vaccination, could have prevented more deaths in older age groups, especially during the early waves. Finally, replicating Bahrain's model as an upper-bound benchmark, Iran could have averted 75,300 (56,000-83,000) deaths, primarily in the > 50 age groups.

conclusionsOur analysis revealed that faster roll-outs were consistently associated with higher numbers of averted deaths, even in scenarios with lower overall coverage. This study offers valuable insights into future decision-making regarding infectious disease epidemic management through vaccination strategies. It accomplishes this by comparing various countries' relative performance in terms of timing, pace, and vaccination coverage, ultimately contributing to the prevention of COVID-19-related deaths.

Indexed as

COVID-19Perinatal DeathVaccinesAgedFemaleHumansIranVaccinationVaccination CoverageVaccinesCounterfactual scenariosCOVID-19Decision-makingExcess mortalityVaccination

Identifiers

PMID37953291
PMCPMC10642021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.